Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
GEMP (Common Stock)
02/16/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.